REPROS THERAPEUTICS INC's ticker is RPRX and the CUSIP is 76028H209. A total of 32 filers reported holding REPROS THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $1,000 | -50.0% | 1,311 | -0.8% | 0.00% | – |
| Q1 2017 | $2,000 | 0.0% | 1,321 | 0.0% | 0.00% | – |
| Q4 2016 | $2,000 | -33.3% | 1,321 | 0.0% | 0.00% | – |
| Q3 2016 | $3,000 | +50.0% | 1,321 | 0.0% | 0.00% | – |
| Q2 2016 | $2,000 | +100.0% | 1,321 | 0.0% | 0.00% | – |
| Q1 2016 | $1,000 | -50.0% | 1,321 | 0.0% | 0.00% | – |
| Q4 2015 | $2,000 | -80.0% | 1,321 | 0.0% | 0.00% | – |
| Q3 2015 | $10,000 | +11.1% | 1,321 | 0.0% | 0.00% | – |
| Q2 2015 | $9,000 | -93.5% | 1,321 | -91.9% | 0.00% | – |
| Q1 2015 | $139,000 | -13.7% | 16,211 | +0.4% | 0.00% | – |
| Q4 2014 | $161,000 | +5.9% | 16,143 | +5.1% | 0.00% | – |
| Q3 2014 | $152,000 | -42.9% | 15,362 | -0.3% | 0.00% | – |
| Q2 2014 | $266,000 | -15.6% | 15,410 | -13.1% | 0.00% | -100.0% |
| Q1 2014 | $315,000 | -3.1% | 17,727 | -0.0% | 0.00% | 0.0% |
| Q4 2013 | $325,000 | -13.3% | 17,731 | +26.5% | 0.00% | 0.0% |
| Q3 2013 | $375,000 | +47.1% | 14,014 | +1.6% | 0.00% | – |
| Q2 2013 | $255,000 | – | 13,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 1,132,367 | $11,290,000 | 4.00% |
| SENZAR ASSET MANAGEMENT, LLC | 764,406 | $7,621,000 | 2.23% |
| DESTRIER CAPITAL MANAGEMENT LLC | 329,030 | $3,280,000 | 0.88% |
| RTW INVESTMENTS, LP | 229,364 | $2,287,000 | 0.85% |
| CQS Cayman LP | 700,000 | $6,979,000 | 0.46% |
| GENERAL AMERICAN INVESTORS CO INC | 508,375 | $5,068,000 | 0.40% |
| Alden Global Capital Ltd | 154,000 | $1,535,000 | 0.37% |
| J. Goldman & Co LP | 197,500 | $1,969,000 | 0.23% |
| Baker Brothers Advisors | 2,000,000 | $19,940,000 | 0.20% |
| SPHERA FUNDS MANAGEMENT LTD. | 100,000 | $997,000 | 0.17% |